Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 8,109.00 |
| Open | 8,118.00 |
| Bid | 8,088.00 x 0 |
| Ask | 8,090.00 x 0 |
| Day's Range | 8,066.00 - 8,204.00 |
| 52 Week Range | 5,871.00 - 10,120.00 |
| Volume | 913,873 |
| Avg. Volume | 1,783,269 |
| Market Cap | 105.85B |
| Beta (5Y Monthly) | 0.22 |
| PE Ratio (TTM) | 49.27 |
| EPS (TTM) | 163.70 |
| Earnings Date | Nov 05, 2020 |
| Forward Dividend & Yield | 2.16 (2.66%) |
| Ex-Dividend Date | Aug 13, 2020 |
| 1y Target Est | 78.83 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Editor's PickYahoo Finance Video
UK launches world's first human challenge trial for COVID-19 with hVivo
Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Anjalee Khemlani discuss hVIVO’s human challenge trial launch for COVID-19, in a Yahoo Finance exclusive interview with Dr. Andrew Catchpole, hVIVO Chief Scientific Officer.
- Editor's PickYahoo Finance Video
Moderna's COVID-19 vaccine timeline
Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and discuss the latest in the COVID-19 vaccine race.
- Zacks
AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Heart Failure
The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of symptomatic chronic HFrEF in adults with and without type-II diabetes.
© 2020 Verizon Media. All rights reserved.
